US2015152160A1PendingUtilityA1
Compositions and methods for modulating immune responses
Est. expiryMay 12, 2025(expired)· nominal 20-yr term from priority
A61P 37/06A61P 37/00A61P 37/02A61P 35/00A61P 43/00A61P 29/00A61P 1/12A61P 1/04A61K 39/3955C07K 16/2803C07K 14/70532A61K 38/00C07K 16/2827C07K 2319/00C07K 2317/73G01N 33/505C07K 16/2818C07K 2317/34C07K 2317/76C07K 2319/30C07K 2317/75A61K 2039/507C12Q 1/66C07K 14/47G01N 2333/70532G01N 33/56972
67
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides a newly identified B7 receptor, zB7R1 that functions as lymphocyte inhibitory receptor, which is a PD-1-like molecule and is expressed on T cells. The present invention also provides the discovery of zB7R1's ability to bind to CD155. Methods and compositions for modulating zB7R1-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic and research purposes are also provided.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A method of treating an immune related disorder in a mammal by administering to said mammal a therapeutically effective amount of a zB7R1 fusion protein.
2 . The method of claim 1 wherein the zB7R1 fusion protein comprises the extracellular domain of B7R1 shown in SEQ ID NO: 3 and an immunoglobulin heavy chain constant region (Fc).
3 . The method of claim 2 wherein the zB7R1 fusion protein is zB7R1-Fc coded by the nucleotide sequence shown in SEQ ID NO: 61.
4 . The method of claim 1 wherein the zB7R1 fusion protein comprises the extracellular domain of B7R1 shown in SEQ ID NO: 3 and the vasodialator-activated phosphoprotein (VASP) tetramerization domain.
5 . The method of claim 4 wherein the zB7R1 fusion protein is zB7R1-VASP coded by the nucleotide sequence shown in SEQ ID NO: 62.
6 . A method of identifying antibodies to zB7R1, the method comprising the steps of:
a. constructing a Baf3-STAT-luciferase reporter cell line expressing a chimera of the extracellular domain of zB7R1 and the transmembrane and intracellular domains of mouse GCSFR; b. incubating antibodies of interest with the Baf3-STAT-luciferase reporter cells; c. isolating the reporter cells from the antibody; d. lysing the reporter cells; e. measuring for activation of the STAT reporter construct by adding luciferase substrate and f. measuring the light generated following addition of substrate.Join the waitlist — get patent alerts
Track US2015152160A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.